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ABSTRACT
Multiple myeloma (MM) is a genetically heterogeneous disease with diverse 
clinical characteristics and outcomes. Recently, multiplex ligation-dependent probe 
amplification (MLPA) has emerged as an effective and robust method for the detection 
of cytogenetic aberrations in MM patients. In the present study, MLPA analysis was 
applied to analyze cytogenetics of CD138 tumor cells of 59 MM samples, and its result 
was compared, retrospectively, with the interphase fluorescence in situ hybridization 
(iFISH) data. We firstly established the normal range of each of the 42 diagnostic 
probes using healthy donor samples. A total of 151 aberrations were detected in 
59 patient samples, and 49/59 cases (83.1%) harbored at least one copy number 
variation. Overall, 0–7 aberrations were detected per case using MLPA, indicating the 
heterogeneity and complexity of MM cytogenetics. We showed the high efficiency of 
MLPA and the high congruency of the two methods to assess cytogenetic aberrations. 
Considering that MLPA analysis is not reliable when the aberration only exits in a small 
population of tumor cells, it is essential to use both MLPA and iFISH as complementary 
techniques for the diagnosis of MM.
INTRODUCTION
Multiple myeloma (MM) is a terminally differentiated 
B cell neoplastic disorder, characterized by the presence 
of clonal proliferation of malignant plasma cells (PCs) in 
bone marrow and excessive monoclonal immunoglobulin 
associated with organ dysfunction [1]. Furthermore, MM 
is also a genetically heterogeneous disease, and whole-
genome screening studies have shown that almost all 
MM patients harbor genetic abnormalities [2–4]. These 
genetic abnormalities can be caused by translocation of 
immunoglobulin heavy chain alleles (IgH) with various 
partner chromosome alleles, copy number variation (CNV) 
or acquired mutation [5]. As complex genome contributes 
to the initiation and progression of MM, cytogenetic 
aberration has emerged as the most important prognostic 
factor and is currently being used to predict the prognosis 
and make medical decisions for therapy [6].
Although conventional metaphase karyotyping offers 
a full view of chromosomes, alterations are only detected 
in 30% of MM cases due to the low mitotic activity of 
MM cells and the low resolution of the technique [7]. 
Interphase fluorescence in situ hybridization (iFISH) is 
able to overcome this shortcoming, and approximately 
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90% of abnormalities are reported when iFISH is applied 
for CD138 tumor cells [8]. Therefore, iFISH has emerged 
as the most viable and widely used approach to detect 
cytogenetic aberrations in MM. However, the problem 
remains since iFISH analysis is a laborious and time-
consuming method with high cost, and is only capable to 
detect deletion or amplification of sequences larger than 
20–50 kb. Furthermore, mutations cannot be detected by 
iFISH. In order to provide detailed evaluation of genomic 
complexity in MM, DNA microarray/comparative genome 
hybridization (CGH), next-generation sequencing (NGS), 
and gene expression profile (GEP) analysis have been 
carried out [8]. Although these novel techniques are more 
sensitive and amenable to higher throughput analysis, 
these assays are still difficult to be used in the routine 
clinical settings due to the cost and turnaround time.
Multiplex ligation-dependent probe amplification 
(MLPA) is a multiplex polymerase chain reaction (PCR) 
method for detecting CNVs up to 50 different genomic 
sequences simultaneously. MLPA probes are able to 
recognize target sequences with 50–100 nucleotides in 
length, which makes it possible to be applied for highly 
fragmented DNA, and the detection of small deletion 
encompassing only a single exon [9]. To date, hundreds of 
special panels have been developed and used successfully 
in the diagnosis of both benign and malignant diseases.
In this study, MLPA analysis was used to detect 
CNVs in MM using purified CD138 cells. The results were 
compared with iFISH data to determine the efficiency of 
MLPA. The combinatorial application of MLPA and iFISH 
in the routine diagnosis of MM was proposed.
RESULTS
Establishment of normal range for each 
individual MLPA probe
The X046-A1 MM probemix contained 53 MLPA 
probes (42 diagnostic probes and 11 reference probes) with 
amplified products between 122 and 499 nt, indicating that 
the PCR reaction efficiency was different among probes. 
As a result, it was inappropriate to use an arbitrary ratio 
range as the sole cutoff value for all probes, which was 
applied in most MLPA studies [10, 11]. Therefore, we 
established a normal range for each diagnostic probe (to be 
prognostically relevant) to improve the accuracy of MLPA 
analysis. A set of 10 DNA samples derived from peripheral 
blood of healthy donors were subjected to MLPA 
analysis. The range of each of the 42 diagnostic probes 
was calculated through two main steps: firstly, within 
every healthy donor sample, the peak area of a specific 
diagnostic probe was divided by the sum of the peak area 
of the 11 reference probes (intra-sample normalization); 
secondly, for each specific healthy donor sample, the peak 
value (derived from the first step) was divided by the 
average of the peak value (derived from the first step) of 
the other 9 healthy donors (inter-sample normalization). 
Finally, 10 values were reckoned for each diagnostic 
probe. There was a small standard deviation (SD) among 
the healthy donors for every probe. Consequently, “Mean 
± 2SD” (95% CI, p = 0.05) and “Mean ± 3SD” (99% CI, 
p = 0.01) values for each individual probe were obtained, 
as listed in Table 1. For better evaluation of the results 
with a larger confidence interval (CI), the “Mean ± 3SD” 
reference range was used as the cutoff value for CNV 
determination in our study.
Abnormalities detected by MLPA
Sixty-four MM samples were subjected to MLPA 
analysis, and 59/64 (92.2%) cases passed the DNA quality 
control and were available for MLPA analysis. Overall, 
151 aberrations were detected in 59 cases, and 49/59 cases 
(83.1%) harbored at least one CNV (Table 2). As shown 
in Figure 1, 0-7 aberrations were detected per case using 
MLPA, indicating the heterogeneity and complexity of 
MM cytogenetics.
1p deletion 1p deletion was detected in 30/59 cases 
(50.8%). There were 9 probes specially designed for 
short arm of chromosome 1, including 5 probes for 1p32, 
2 probes for 1p31 and 2 probes for 1p21. Eleven cases 
only had one probe abnormality; while 8 cases displayed 
1p deletion covering more than 3 probes. The DPYD gene 
at 1p21.3 was the most frequently affected gene (18/30), 
followed by PPAP2B at 1p32.2 (17/30), and COL11A1 at 
1p21.1 (12/30).
1q amplification 1q amplification was detected in 
32/59 cases (54.2%). Ten probes located in long arm of 
chromosome 1, including 2 probes for 1q21 and 8 probes 
for 1q23. Twenty-eight cases harbored large fragment 
amplification, which involved at least 4 probes, while 
only 4 cases showed amplification of less than 4 probes. 
All these 32 cases harbored 1q23 amplification, while 
22 cases showed amplification of both 1q21 and 1q32. 
Contrary to 1p deletion, 1q amplification often represented 
large segment amplification, and 1q32 was more prone to 
amplification. In addition, 1q deletion was also detected in 
one case (#18) (* in Table 2). The involved probes were 
RP11–541J2 and RP11–480N10, which located at 1q23.3. 
However, the two probes spanned a gene-poor region, 
which rarely indicated prognostic impacts.
5q amplification 5q amplification was detected in 
13/59 cases (22.0%). Six probes were included for the 
evaluation of 5q31.3. Eleven cases showed amplification 
covering more than 3 probes, while the other 2 cases 
showed amplification of only one single probe. However, 
3 cases (#18, #47, #59) were detected to possess 5q 
deletion (* in Table 2). Sample #47 had deletion of all the 
six probes, while #18 and #59 had only two and one probe 
deletion, respectively.
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Table 1: Normal reference range established for each individual probe for MM MLPA
Target 
regions
Gene/Exon Normal range (Mean ± 2SD; 95% CI,  
p = 0.05)
Normal range (Mean ± 3SD; 99% 
CI, p = 0.01)
1p32.3 FAF1, ex 4 0.85–1.17 0.77–1.25
1p32.3 CDKN2C, ex 3 0.83–1.19 0.75–1.28
1p32.3 PPAP2B, ex 1b 0.93–1.10 0.89–1.15
1p32.2 DAB1, ex 14 1.00–1.20 0.95–1.24
1p32.2 DAB1, ex 2 0.87–1.14 0.80–1.21
1p31.3 LEPR, ex 4 0.92–1.20 0.85–1.27
1p31.2 RPE65, ex 14 0.81–1.17 0.72–1.26
1p21.3 DPYD, ex 5 0.82–1.02 0.76–1.07
1p21.1 COL11A1, ex 45 0.78–1.07 0.71–1.14
1q21.3 CKS1B, ex 1b 0.81–1.15 0.72–1.24
1q21.3 CKS1B, ex 2 0.82–1.18 0.73–1.27
1q23.3 NUF2, ex 1b 0.83–1.13 0.75–1.21
1q23.3 NUF2, ex 14 0.90–1.14 0.84–1.20
1q23.3 RP11–541J2 0.80–1.16 0.71–1.25
1q23.3 RP11–541J2 0.91–1.16 0.85–1.22
1q23.3 RP11–541J2 0.82–1.05 0.76–1.10
1q23.3 RP11–541J2 0.76–1.15 0.67–1.24
1q23.3 RP11–480N10 0.82–1.12 0.75–1.20
1q23.3 PBX1, ex 9 0.87–1.17 0.80–1.25
5q31.3 PCDHA1, ex 1b 0.78–1.13 0.70–1.22
5q31.3 PCDHAC1, ex 1a 0.76–1.07 0.69–1.15
5q31.3 PCDHB2, ex 1 0.81–1.10 0.74–1.17
5q31.3 PCDHB10, ex 1 0.82–1.06 0.76–1.13
5q31.3 SLC25A2, ex 1 0.75–1.34 0.61–1.48
5q31.3 PCDHGA11, ex 1b 0.94–1.08 0.91–1.12
12p13.31 CD27, ex 3 0.79–1.08 0.72–1.15
12p13.31 VAMP1, ex 4b 0.78–1.06 0.71–1.13
12p13.31 NCAPD2, ex 2 0.84–1.17 0.76–1.25
12p13.31 NCAPD2, ex 32 0.74–1.18 0.63–1.29
12p13.31 CHD4, ex 40 0.80–1.13 0.72–1.21
12p13.31 CHD4, ex 2 0.67–1.15 0.55–1.27
13q14.2 RB1, ex 7 0.83–0.98 0.80–1.02
13q14.2 RB1, ex 27 0.75–1.18 0.65–1.28
13q14.3 DLEU2, ex 2 0.87–1.12 0.81–1.18
13q14.3 DLEU1, down 0.82–1.06 0.77–1.12
16q12.1 CYLD, ex 2 0.75–1.33 0.60–1.48
16q12.1 CYLD, ex 19 0.86–1.02 0.82–1.06
(Continued )
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12p deletion 12p deletion was detected in 12/59 
cases (20.3%). Six probes hybridized to 12p13 were 
involved. Seven cases showed the loss of all six probes, 
indicating the large fragment deletion of 12p13. The 
other five cases showed only 1 or 2 probe abnormalities. 
The most frequently effected probes were CD27 (9/12), 
NCAPD2–2 (9/12) and CDH4–2 (9/12). However, we 
also found 3 cases (#37, #41, #55) with NCAPD2–2 
amplification (* in Table 2).
13q deletion 13q deletion was detected in 36/59 
cases (61.0%), which presented the most frequent 
aberration detected by MLPA. Two probes were 
designed for 13q14.2, while 2 probes were designed for 
13q14.3. Thirty-one cases had the loss of large fragment, 
which involved at least 3 probes. The most frequently 
affected probe was RB1–7 (34/36), followed by DLEU1-
down (33/36).
16q deletion 16q deletion was detected in 14/59 
cases (23.7%). CYLD-2/-19 probes were particularly 
designed for 16q14.2, while WWOX-1/-8 probes were 
designed for 16q23.1. Ten cases showed the loss of at 
least 2 probes, and the most frequently affected probe was 
CYLD-19 (12/14), followed by WWOX-7 (10/14).
17p deletion 17p deletion was detected in 7/59 
cases (11.9%). The 3 probes could target different exons 
of TP53, and were found lost in all 7 cases.
Prognostic values of aberrations detected 
by MLPA
These chromosomal aberrations detected by 
iFISH have already been found prognostically relevant. 
For instance, 5q31.3 amplification was reported to 
be a favorable prognostic factor of MM [2], while 
amplification of 1q, deletion of 1p, 12p, 13q, 16q and 
17p were correlated with poor prognosis [5]. To explore 
the prognostic value of the same aberrations detected 
by MLPA, survival analysis was carried out in 54 MM 
samples with available follow up data. The results showed 
that patients with del(12p) had markedly shortened 
PFS (10.6 vs. 23.2 months, p = 0.001) and OS (12.8 
vs. 27.8 months, p = 0.001) than those without del(12p) 
(Figure 2A and 2D). Meanwhile, patients with del(17p) 
were significantly worse than those without del(17p) with 
a median PFS of 10.2 vs. 21.8 months (p  = 0.039) 
and a median OS of 10.5 vs. 26.3 months (p = 0.023) 
(Figure 2B, 2E). Moreover, 13q deletion could also cause 
shortened PFS of 16.9 vs. 27.6 months (p = 0.009) and OS 
of 29.8 vs. 22.2 months (p = 0.049) (Figure 2C and 2F). 
While the other aberrations, namely 1q amplification, 1p 
deletion and 16q deletion, failed to exhibit prognostic 
value separately. This may be caused by the small patient 
sample size and different treatment strategies. However, 
we found that three patients had at least five adverse 
lesions with a median OS of 2.5 months and a median PFS 
of 1.2 months, while patients with 1–4 adverse lesions 
had a median OS of 25.6 months and a median PFS of 
20.4 months (p < 0.001).
Comparison of MLPA and iFISH
To evaluate the performance of MLPA as a 
candidate diagnostic method for the identification of 
CNVs in MM, iFISH results of 59 cases were studied 
retrospectively and compared with MLPA results directly. 
The frequency of genetic lesions determined by iFISH 
and MLPA was listed in Table 3, and the combinatorial 
application of iFISH and MLPA revealed that 54/59 cases 
(91.5%) had at least one cytogenetic lesion.
Three abnormalities, including 1q amplification, 
13q deletion and 17p deletion were detected by both 
iFISH and MLPA. Out of 177 (3 × 59) comparisons, 
156 results were concordant, and the whole consistency 
was 88.1%. The McNemar test was used for the 
comparison between iFISH and MLPA. As shown in 
Table 4, there were no significant differences between 
iFISH and MLPA results of 1q amplification and 17p 
deletion. The sensitivity and specificity of MLPA to 
determine 1q amplification were 91.4% and 100%; 
while the sensitivity and specificity of 17p deletion 
were 77.8% and 100%, respectively. The most obvious 
difference was observed in the determination of 13q 
deletion, with the sensitivity of 88.5% and the specificity 
of 60.6%.
In 13 cases, 13q deletion was only detected by 
MLPA rather than iFISH. As displayed in Table 5, 4 cases 
(#5, #9, #18, #53) had only one probe deletion, which may 
lead to negative results of iFISH due to mutations or low 
resolution of the approach. Nevertheless, the remaining 
9 cases with the abnormalities of at least 3 probes, 
spanning chromosomal regions including 13q14.2 and 
13q14.3 were not detected by iFISH.
Target 
regions
Gene/Exon Normal range (Mean ± 2SD; 95% CI,  
p = 0.05)
Normal range (Mean ± 3SD; 99% 
CI, p = 0.01)
16q23.1 WWOX, ex 1a 0.82–1.04 0.76–1.09
16q23.1 WWOX, ex 8 0.93–1.08 0.89–1.12
17p13.1 TP53, ex 11 0.81–1.18 0.72–1.27
17p13.1 TP53, ex 8 0.85–1.05 0.80–1.10
17p13.1 TP53, ex 5 0.76–1.12 0.671.21
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Table 2: Summary of abnormalities detected by MLPA for per case
Sample number Target region (number of affected probes/total number of probes)
Del (1p) Amp (1q) Amp (5q) Del (12p) Del (13q) Del (16q) Del (17p)
#1 1/9 4/10 5/6 ND 3/4 ND ND
#2 ND ND ND ND 4/4 ND ND
#3 ND 8/10 ND ND ND 1/4 ND
#4 1/9 ND 1/6 ND ND ND ND
#5 5/9 9/10 ND 1/6 1/4 2/4 ND
#6 ND ND ND 6/6 4/4 ND ND
#7 ND ND ND ND ND ND ND
#8 3/9 ND ND 6/6 4/4 ND 3/3
#9 1/9 10/10 5/6 ND 1/4 ND 3/3
#10 ND ND ND ND ND ND ND
#11 1/9 9/10 ND ND 4/4 ND ND
#12 1/9 ND ND ND ND ND ND
#13 ND ND ND ND 3/4 ND ND
#14 1/9 9/10 4/6 ND 3/4 4/4 ND
#15 ND 10/10 ND ND 4/4 ND ND
#16 ND ND ND ND 4/4 ND ND
#17 7/9 10/10 5/6 ND ND ND ND
#18 6/9 3/10* 2/6* 2/6 1/4 ND ND
#19 ND ND ND ND 4/4 ND ND
#20 2/9 10/10 ND 1/6 4/4 4/4 3/3
#21 ND ND ND ND ND ND ND
#22 ND 10/10 ND ND ND ND ND
#23 ND 10/10 ND ND ND ND ND
#24 ND ND ND ND 4/4 ND ND
#25 7/9 8/10 ND ND 4/4 ND ND
#26 ND ND ND ND 4/4 ND 3/3
#27 2/9 3/10 ND ND 3/4 3/4 ND
#28 1/9 ND ND 6/6 4/4 ND ND
#29 2/9 2/10 1/6 1/6 4/4 ND ND
#30 9/9 ND ND ND 4/4 4/4 3/3
#31 ND ND ND 1/6 ND ND ND
#32 8/9 4/10 ND 6/6 3/4 ND ND
#33 3/9 4/10 ND ND 3/4 ND ND
#34 1/9 9/10 ND ND ND ND ND
#35 3/9 5/10 5/6 ND 3/4 1/4 ND
#36 ND ND ND ND ND ND ND
(Continued )
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It is worth noting that there were still 8 aberrations 
only detected by iFISH but not by MLPA, although MLPA 
showed a higher resolution. The discordant results were 
listed in Table 6. MLPA failed to detect the aberrations 
when the particular lesion was only present in a relatively 
small population. In detail, the clonal size of cases with 
13q14 deletion detected by iFISH was 31%–100% (73.9 
± 22.9%), while cases not detected by MLPA (#58, #45, 
#57) possessed positive clones of 31%, 33% and 39%, 
respectively. For another example, the clonal size of 17p 
deletion detected by iFISH was 24.5%–97.5% (69.3 ± 
22.4%), while cases not determined by MLPA (#6, #24) 
had positive clones of 24.5% and 46%. The similar 
situation occurred in 1q21 with the value 22.5%–100% 
(70.3 ± 25.3%). Cases #48, #12 and #40 had positive 
clones of 32%, 39% and 51%, respectively. Therefore, 
MLPA was prone to false negative results when the 
particular lesions occurred in a relatively small population.
DISCUSSION
Although MM patients present common histological 
and morphological diagnosis, MM displays enormous 
cytogenetic complexity and marked variations in clinical 
characteristics and outcomes. Thereby, risk stratification 
and prognosis assessment based on cytogenetic changes 
are important for treatment of MM. It has been well 
established that del(17p), t(4;14) and t(14;16) confer 
high risk of MM [3, 12]. However, some other certain 
cytogenetic changes also reveal significant impacts on 
outcomes. Several research groups have demonstrated 
that amp(1q), del(1p), del(12p) and del(16q) are adverse 
prognostic markers of MM [13–18]. Recent studies have 
also found that del(6q) worsen the prognosis of patients 
with del(17p) [19]. Therefore, it is highly necessary 
to reveal all prognostically relevant lesions in MM 
cells. Nevertheless, it is difficult for iFISH to screen all 
Sample number Target region (number of affected probes/total number of probes)
#37 5/9 4/10 5/6 1/6* 3/4 3/4 ND
#38 ND ND ND ND ND ND ND
#39 ND 10/10 6/6 ND ND ND ND
#40 ND ND ND ND ND ND ND
#41 ND 2/10 5/6 1/6* ND ND ND
#42 7/9 10/10 ND ND 4/4 ND ND
#43 ND ND ND ND ND ND ND
#44 ND ND ND ND ND ND ND
#45 ND ND ND ND ND ND ND
#46 ND 4/10 4/6 ND ND ND ND
#47 2/9 3/10 6/6* 6/6 4/4 3/4 3/3
#48 ND ND ND ND 1/4 2/4 ND
#49 ND 10/10 ND ND 3/4 ND ND
#50 3/9 10/10 ND ND 3/4 ND ND
#51 2/9 10/10 4/6 ND 3/4 3/4 ND
#52 2/9 8/10 5/6 ND 4/4 ND ND
#53 1/9 6/10 ND ND 1/4 1/4 ND
#54 ND 10/10 ND ND ND ND ND
#55 ND ND ND 1/6* 3/4 3/4 ND
#56 1/9 9/10 ND ND 4/4 1/4 ND
#57 2/9 10/10 ND 6/6 ND ND 3/3
#58 ND ND ND ND ND ND ND
#59 1/9 ND 1/6* 6/6 4/4 ND ND
Del, deletion; Amp, amplification; ND, not detected.
Those with * are abnormalities different from the general situation, which would be discussed in detail in the results section.
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lesions simultaneously due to the high cost and technique 
limitation.
MLPA can analyze up to 50 CNVs in a single 
PCR reaction. Owing to the high throughput capability 
of the technique, MLPA analysis kit can be updated 
rapidly according to the latest research progress in 
cytogenetic study. For example, compared with SALSA 
P425-A1 kit, P425-B1 kit also contains probes related to 
amplification of chromosome 9 and 15 [10]. As a result, 
MLPA has emerged as an effective and robust method 
for the diagnosis of many diseases. In this study, we used 
MLPA to scan CNVs that are closely associated with MM 
prognosis based on published literature. However, we did 
not use a universal cutoff value for all probes. Instead, 
we established a normal range for each individual probe 
using a panel of 10 healthy donor samples. This will 
eliminate the difference in PCR efficiency of each probe 
and increase the accuracy of the experiments. To the best 
of our knowledge, this is the first report on the use of a 
specific range for each probe in MM investigation using 
MLPA. Donat et al. have used the same MLPA panel to 
detect CNVs in 81 MM patients [11]. The frequencies of 
1q, 5q amplification and 12p, 13q, 16q, 17p deletion in our 
cohort are consistent with previous reports. The highest 
inconsistency occurred in the determination of 1p deletion, 
which was 35% in our study and 50.8% in Donat’s 
study. The possible reason for this discrepancy is the 
different cutoff value. Values below or equal to 0.75 were 
considered as loss in Donat’s study, while the cutoff value 
was higher than 0.75 in 6/9 probes in our study (Table 1). 
When the same cutoff value in Donat’s study was applied, 
the 1p deletion rate was 40.0% in our cohort. Therefore, 
the “custom built” cutoff value improves the sensitivity of 
1p detection by MLPA. However, whether the increased 
sensitivity is accompanied by false positive rate still 
needs investigation with a larger sample size and by other 
techniques.
MLPA results were compared with iFISH data 
because iFISH is the most commonly used method. 
Although there is a great concordance between iFISH 
and MLPA, some discrepancies still exist. In our study, 
the highest discrepancy exists in 13q deletion, with 
especially low specificity of 60.6%. The discrepancy may 
result from different probes used in the two techniques. 
In our study, del(13q) abnormality detected by iFISH was 
analyzed with the probe specific for 13q14.1–13q14.3 
locus (LSI RB-1), which is approximately 220 kb and 
contains sequences targeting the entire RB1 gene. 
While in MLPA analysis, the two probes located in 
13q14.2 only target exon 7 and exon 27 of RB-1 gene. 
The different resolution of the two techniques may be 
a reason of the differences. Moreover, the genes DLEU-1 
and DLEU-2, targeting 13q14.3 in MLPA, located about 
2.0 Mb far from the probe LSI RB-1 [20]. So some MM 
patients with 13q14.3 deletion may not be detected by 
iFISH in our study.
Figure 1: Number of aberrations present in each case detected by MLPA in this study.
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To conclude, discrepancies between the two methods 
may be related to three major reasons: different resolution, 
point mutation and subclone. Firstly, iFISH analysis is only 
able to detect deletion or amplification of sequences larger 
than 20–50 kb, while MLPA can recognize sequences of 
50–100 nt in length. Consequently, the application by 
MLPA can achieve the detection of highly fragmented 
cryptic lesion. Secondly, mutation or polymorphism in the 
sequence detected by a probe can also result in reduction of 
the relative peak area in MLPA analysis, which cannot be 
picked up by iFISH. Usually, several different probes for a 
specific gene or different genes in the same chromosomal 
region are used in a MLPA kit. It is much more reliable 
when several related probes show the same aberration 
Figure 2: Survival analysis in MM patients harboring specific aberration detected by MLPA. Progression free survival 
(PFS) of MM patients harboring del(12p) A. del(17p) B. del(13q) C. Overall survival (OS) of MM patients harboring del(12p) D. del(17p) 
E. del(13q) F.
Table 3: Frequency of genetic lesions determined by iFISH and MLPA (N = 59)
iFISH % (n = ) MLPA % (n = )
Del (1p) NA 50.8% (n = 30)
Amp (1q) 59.3% (n = 35) 54.2% (n = 32)
Amp (5q) NA 22.0% (n = 13)
Del (12p) NA 20.3% (n = 12)
Del (13q) 44.1% (n = 26) 61.0% (n = 36)
IgH 54.2% (n = 32) NA
Del (16q) NA 23.7% (n = 14)
Del (17p) 14.1% (n = 9) 11.9% (n = 7)
Overall 84.7% (n = 50) 83.1% (n = 49)
Del, deletion; Amp, amplification; NA, not analysis.
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simultaneously. However, it is often ambiguous when only 
one single probe is used for the detection of abnormality. 
We cannot discriminate mutation or deletion without using 
other methods. Thirdly, with the development of novel 
technologies, such as CGH and NGS, clonal heterogeneity 
and clonal evolution have emerged as critical concepts in 
the field of oncology, especially in the pathogenesis of 
MM [21–23]. It is well known that genetic hits in MM 
Table 4: Sensitivities and specificities of MLPA compared with iFISH
iFISH
Amp (1q) Del (13q) Del (17p)
+ − + − + −
MLPA + 32 0 23 13 7 0
− 3 24 3 20 2 50
McNemar
Test p = 0.250 p = 0.021 p = 0.500
Del, deletion; Amp, amplification.
Table 5: Detailed discordances between MLPA and iFISH: aberrations only detected by MLPA but 
not iFISH (n = 13)
Sample number iFISH mosaic (%) Target regions (genes)
#5 2.5 13q14 (DLEU1)
#9 1.5 13q14 (RB1–7)
#14 3 13q14 (RB1–7,DLEU2,DLEU1)
#16 4 13q14 (RB1–7,RB1–27,DLEU2,DLEU1)
#18 5 13q14 (RB1–7)
#27 1 13q14 (RB1–7,DLEU2,DLEU1)
#29 0.5 13q14 (RB1–7,RB1–27,DLEU2,DLEU1)
#35 13.5 13q14 (RB1–7,DLEU2,DLEU1)
#37 4 13q14 (RB1–7,DLEU2,DLEU1)
#42 11 13q14 (RB1–7,RB1–27,DLEU2,DLEU1)
#51 3 13q14 (RB1–7,DLEU2,DLEU1)
#53 2.5 13q14 (DLEU1)
#55 5.5 13q14 (RB1–7,DLEU2,DLEU1)
Table 6: Detailed discordances between MLPA and iFISH: aberrations only detected by iFISH but 
not by MLPA (n = 8)
Sample number iFISH mosaic (%) Target regions (genes)
#12 39 1q21 (CKS1B)
#40 51 1q21 (CKS1B)
#48 32 1q21 (CKS1B)
#45 33 13q14 (RB1)
#57 39 13q14 (RB1)
#58 31 13q14 (RB1)
#6 24.5 17p13 (TP53)
#24 46 17p13 (TP53)
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are acquired not only in a linear fashion but also through 
a branching pattern [24]. In another word, subclones 
carrying different aberrations and distinct phenotypes may 
coexist in a single MM patient. However, MLPA analysis 
of tumor samples provides information of the total cells 
using their extracted DNA. If specific genetic aberration 
exists only in a very small subclone, it is likely not going 
to be detected. On the contrary, aberration present in 
each single tumor cell can be detected by iFISH. This is 
an important difference between these two methods. It is 
reported that MLPA will be effective when the abnormality 
is present in more than 30% of analyzed cells [11, 25]. But 
in our study, the threshold was more likely to be around 
50%. The disparity may be caused by the differences in 
the contents of tumor cells. In Donat’s study, tumor cell 
enrichment was applied only when the proportion of PCs 
was less than 20%–25%, while our MLPA analysis was 
conducted solely on purified CD138 cells. Therefore, we 
can conclude that the content of tumor cells has a great 
impact on the sensitivity of MLPA analysis, especially for 
MM diagnosis. Our previous study has demonstrated that 
prognostic values can be observed when patients harbor 
a small clone of 13q deletion or 1q21 amplification, such 
as 10% for 13q deletion and 20% for 1q21 amplification 
[13]. As a result, MLPA analysis is not reliable when 
the aberration only exits in a very small population of 
tumor cells.
Furthermore, MLPA failed to detect IgH 
translocation, which accounts for 40%–50% of primary 
cytogenetic events in MM and strongly influences disease 
phenotype and prognosis. This shortage of MLPA makes 
iFISH irreplaceable. Taken together, MLPA can detect 
CNVs in a high throughput fashion with higher resolution, 
while iFISH can detect both balanced and unbalanced 
rearrangements and are more reliable to detect aberrations 
existing in a small subclone. MLPA and iFISH analysis are 
mutually complementary for the detection of cytogenetic 
aberrations of myeloma.
MATERIALS AND METHODS
Patients and sample preparation
Bone marrow samples from 64 newly diagnosed 
MM patients were obtained at The Institute of Hematology 
and Blood Disease Hospital from August 2011 to 
March 2013. The male to female ratio was 40/24, and 
the median age of the patients was 58 years old (range: 
25–75 years old) with the median follow-up time of 
17 months (range: 0–36 months) from the time point of 
sample collection. Ten peripheral blood samples from 
healthy donors were also collected. All patients and 
healthy donors signed an informed consent form approved 
by institutional local ethics committee.
Mononuclear cells (MNCs) from MM patients 
and healthy donors were isolated by gradient density 
centrifugation (Ficoll-Hypaque; Eurobio, Les Ulis, 
France). Malignant PCs were purified from MM samples 
using the Miltenyi technology (anti-CD138-coated 
magnetic beads) as described previously to ensure plasma 
cell purity of higher than 90% [12].
Interphase FISH analysis
Interphase FISH analysis was used to detect 
cytogenetic aberrations in purified PCs of MM. In detail, 
Del (13q) abnormality was analyzed with the probe specific 
for the 13q14 locus (LSI RB-1, Abbott Laboratories). 
Del (17p13) was assessed using a probe specific for the 
17p13.1 locus (LSI p53, Abbott Laboratories). In order to 
detect the amplification of 1q21, we used 1q21 (CKS1B) 
probe (GP Medical Technologies, Beijing). The LSI IGH/
FGFR3 dual-color probe (Abbott Laboratories), LSI 
IGH/CCND1 XT probe (Abbott Laboratories) and IGH/
MAF DF probe (Abbott Laboratories) were used to detect 
t(4;14), t(11;14), and t(14;16), respectively.
A total of 200 interphase nuclei were analyzed. 
Cut-off values recommended by the European Myeloma 
Network (EMN) were used. For the deletion and 
numerical aberration, the cut-off level was set at 20%; for 
translocation in IgH locus as well as other translocation, 
the cut-off level was set at 10% [26].
MLPA analysis
DNA was extracted using QIAamp DNA mini kit 
(Qiagen, Hilden, Germany), and subjected to MLPA 
analysis using SALSA kit X046-A1 that was renamed 
as SALSA P425-A1 (kindly donated by MRC Holland, 
Amsterdam, Netherlands). The probe mix contained 
42 probes for the following chromosomal regions such 
as 1p32-p21, 1q21.3, 1q23.3, 5q31.3, 12p13.31, 13q14, 
16q12, 16q23 and 17p13. These probes could predict 
prognostic relevance in MM. In addition, 11 reference 
probes were included in this probe mix for detecting 
11 different chromosomal locations with relative quietness 
in MM. MLPA reactions were performed according to the 
manufacturer’s instructions. Finally, the PCR products 
were analyzed using an ABI 3130 capillary sequencer 
(Applied Biosystems, Foster City, CA, USA) and http://
Coffalyser.Net software (MRC Holland, Amsterdam, 
Netherlands) (Supplementary Figure).
Statistical analysis
The McNemar test was used for the comparison 
between MLPA and iFISH for the aberration detection. 
Survival curves were plotted by the Kaplan-Meier 
method, and the difference was assessed by log-rank test. 
Progression free survival (PFS) was calculated from the 
initiation of therapy to the date of death, progression or 
last follow-up. Overall survival (OS) was measured from 
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the initiation of treatment to the date of death or last 
follow-up according to the International uniform response 
criteria [27]. The statistically significant difference was 
considered at p < 0.05.
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